|
Report No. : |
342260 |
|
Report Date : |
26.09.2015 |
IDENTIFICATION DETAILS
|
Name : |
CHEN HO PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
No.23, Xingong Rd., Xinying Dist., Tainan
City 730 |
|
|
|
|
Country : |
Taiwan |
|
|
|
|
Date of Incorporation : |
17.07.1973 |
|
|
|
|
Com. Reg. No.: |
72004856 |
|
|
|
|
Legal Form : |
Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacturing and sales of western medicine |
|
|
|
|
No. of Employee : |
About 150 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Taiwan |
A1 |
A1 |
|
Risk Category |
ECGC Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
|
Company Name: |
|
|
Supplied Name: |
|
|
Trading Address: |
No.23, Xingong
Rd., Xinying Dist., Tainan City 730, Taiwan (R.O.C.) |
|
Supplied Address: |
|
|
Telephone Number: |
+886-6-652-9311 |
|
Fax Number: |
Notes: The exact name and address are as above.
Subject was incorporated
on 1973-07-17 with registered number 72004856
as Joint Stock Company in Taiwan.
|
Former English Name: |
Chen-Ho Pharmaceuticals Co., Ltd. |
|
Current English Name: |
Chen Ho Pharmaceutical Co., Ltd. |
Factory
|
Name: |
Chen Ho Pharmaceutical Co., Ltd.Xinying
Plant |
|
Address: |
No. 23, Xingong Rd, Jiafangli, Xinying Dist, Tainan City |
|
Date of Foundation: |
1986-04-28 |
|
Date of Registration: |
1988-06-30 |
|
Factory Registration Number: |
99659061 |
|
Factory Manager: |
Wang Zhenghe |
|
Status: |
In production |
|
Date of Last Annual Return: |
2011-10-27 |
|
Major Products: |
092 Non-alcoholic beverage 200 Medicines and medical chemicals |
Branches
|
1 |
|
|
Name |
Taipei Branch |
|
Address: |
4/F., No.46, Sec.1, Chengde Rd., Taipei City, Taiwan |
|
Tel: |
+886-2-2555-4393 |
|
Fax: |
+886-2-2558-4228 |
|
2 |
|
|
Name |
Kaohsiung Branch |
|
Address: |
11/F., No.150, Jiuru 2nd Rd., Kaohsiung City, Taiwan |
|
Tel: |
+886-7-311-2238 |
|
Fax: |
+886-7-311-3822 |
|
3 |
|
|
Name |
Tainan Branch |
|
Address: |
No.8, Xintai Rd., Yanshui Township, Tainan County, Tainan, Taiwan |
|
Tel: |
+886-6-698-6909 |
|
Fax: |
+886-6-693-5413 |
|
4 |
|
|
Name |
R & D Center |
|
Address: |
No.21, Xingong Rd., Xinying Dist., Tainan
City 730, Taiwan |
|
Tel: |
+886-6-652-9311 |
|
Fax: |
+886-6-653-2319 |
Major Shareholders
|
Name |
Subscription Shares |
|
Zhenghe Wang |
|
|
1,733,930 |
|
|
Peiyu Wang |
437,294 |
|
Yunwen Wang |
405,834 |
|
Weiping Wang |
388,894 |
|
Yujie Wang |
857,659 |
|
Huiyi Wang |
404,019 |
Core Management
Directors
|
1 |
||
|
Name |
Zhenghe Wang |
|
|
Position |
President |
|
|
2 |
||
|
Name |
Peiyu Wang |
|
|
Position |
Director |
|
|
3 |
||
|
Name |
Yunwen Wang |
|
|
Position |
Director |
|
|
4 |
||
|
Name |
Weiping Wang |
|
|
Position |
Director |
|
|
5 |
||
|
Name |
Yujie Wang |
|
|
Position |
Director |
|
|
6 |
||
|
Name |
Huiyi Wang |
|
|
Position |
Supervisor |
|
Personnel Structure
|
Total Employees |
About 150 Employees |
Offices & Factories
|
|
Headquarters |
|
Add |
No.23, Xingong Rd., Xinying Dist., Tainan City 730, Taiwan (R.O.C.) |
Production
Information
Subject is engaged in manufacturing of western medicine
Subject has a factory in Taiwan for production.
It is introduced that subject has received the GMP approval.
Purchase
Information
The registered activities of subject:
|
No. |
Details |
|
1 |
Chinese and western medicine manufacturing business |
|
2s |
The pharmaceutical and food related processing and manufacturing
industry |
The raw materials for production are purchased from both home and
abroad.
Sales Information
Subject is engaged in sales of western
medicine
The major products are medicine of endocnne, cardiovascular system,
common clod preparation, antibiotic, central nerve system, extemal agent,
gastrointestinal tract and diabetes, etc.
Subject’s sales regions include domestic market, Southeast Asia, America
and Europe
Subject’s major customers are hospital, clinic and pharmacy
Import and export right:
|
Import right |
Yes |
|
Export right |
Yes |
Purchase
Domestic Purchase
|
Products |
Raw materials |
|
Payment Terms |
T/T, Cash |
Import
|
Products |
Raw materials |
|
Payment Terms |
L/C, T/T |
Domestic Markets
|
Product |
Western medicine |
|
Selling Terms |
T/T, Cash |
Export
|
Product |
Western medicine |
|
Selling Terms |
L/C, T/T |
Subject has no obligations to disclose its
financial statements to the third party according to the relevant policy in
Taiwan and the only source from which we can obtain the information is the
subject itself.
Subject’s relevant staff declined to disclose
its financials citing the grounds of company’s confidentiality; from other
sources we could not obtain such information, either.
Subject declined to disclose its bank details; from other source we
could not obtain the relevant information, either.
Mortgage
No chattel mortgage record of subject has been found within the recent 3
months.
Lawsuit
Up to date of reporting, no existing or latent
litigation of the subject has been found.
Interview Details
|
Name |
Ms. Wang |
|
Department |
Sales Department |
|
E-mail |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.66.10 |
|
|
1 |
Rs.100.89 |
|
Euro |
1 |
Rs.73.96 |
INFORMATION DETAILS
|
Analysis Done by
: |
RAS |
|
|
|
|
Report Prepared
by : |
ANK |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.